The JUPITER study, presented at the American College of Cardiology (AHA) meeting in New Orleans, has sparked significant discussion about the use of statins in patients with low LDL-C but elevated CRP levels. The trial focused on rosuvastatin and found that it significantly reduced the risk of major cardiovascular events—such as heart attacks, strokes, unstable angina, and vascular revascularization—by 44% in this group. Despite these promising results, current guidelines do not recommend statin therapy for individuals who don’t meet traditional lipid thresholds. Some experts argue that the findings are too early to change existing treatment protocols.
Research shows that nearly half of all heart attacks and strokes occur in people who appear healthy with normal or low LDL-C levels. High-sensitivity C-reactive protein (hsCRP) is a key inflammatory marker that independently predicts future cardiovascular events. Statins have more than just lipid-lowering effects; they also reduce inflammation, a benefit known as pleiotropy. A 2001 study showed that patients with low LDL-C but high hsCRP had similar risk levels to those with hyperlipidemia, suggesting that statins could help reduce their risk.
JUPITER aimed to test this theory by enrolling 17,802 men over 50 and women over 60 from 216 countries. Participants had LDL-C below 130 mg/dL and hsCRP above 2.0 mg/L, with no history of cardiovascular disease or diabetes. They were randomly assigned to receive either 20 mg/day of rosuvastatin or a placebo. After the trial, LDL-C dropped by 50% to an average of 55 mg/dL, and hsCRP decreased by 37%. The primary endpoint—heart attack, stroke, revascularization, hospitalization for angina, or cardiovascular death—occurred in 0.77% of the rosuvastatin group versus 1.36% in the placebo group. The hazard ratio was 0.56, showing a clear benefit.
Lead researcher Dr. Paul Ridker from Harvard Medical School highlighted the cost-effectiveness of using rosuvastatin for primary prevention. He noted a 47% reduction in hospitalizations and revascularizations during follow-up, suggesting that screening and treating based on CRP could be a valuable strategy. Among participants with only elevated CRP as a risk factor, the first event rate dropped by 37%, reinforcing the link between inflammation and cardiovascular risk.
In terms of safety, rosuvastatin was well-tolerated. There were no significant differences in muscle-related side effects between the groups. Notably, cancer deaths were lower in the rosuvastatin group (35 vs. 58), though overall cancer incidence remained similar. However, more cases of diabetes were reported in the rosuvastatin group (245 vs. 196), consistent with findings from other statin trials.
The exact mechanism by which rosuvastatin reduces CRP and event rates is still unclear. While all statins have anti-inflammatory properties, rosuvastatin appears particularly effective in both lowering LDL-C and reducing inflammation. This study opens new possibilities for targeting inflammation in cardiovascular prevention.
Food Additive Monosodium Glutamate 98%
Cheap Food Additives,Good Food Additive,Food Additive Bha,Additive Monosodium Glutamate
JILIN COFCO BIO-CHEM AND BIO-ENERGY MARKETING CO., LTD , https://www.cofco-biotech.com